In 2002, Nakov et al. [15] conducted a multicenter randomized, double-blind clinical trial to evaluate the efficacy of Darusentan, a selective ETAR antagonist, in patients with moderate HTN, defined as resting diastolic office BP in sitting position between 100 and 109 mmHg at baseline. The gene discussed is EDNRA; the disease is hypertensive disorder.